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Summary
Objectives: To evaluate the methodological quality of the
Palestinian Clinical Practice Guideline for Diabetes Mellitus
using the Translated Arabic Version of the AGREE II.
Design: Methodological evaluation. A cross-cultural adap-
tation framework was followed to translate and develop a
standardised Translated Arabic Version of the AGREE II.
Setting: Palestinian Primary Healthcare Centres.
Participants: Sixteen appraisers independently evaluated
the Clinical Practice Guideline for Diabetes Mellitus using
the Translated Arabic Version of the AGREE II.
Main outcome measures: Methodological quality of dia-
betic guideline.
Results: The Translated Arabic Version of the AGREE II
showed an acceptable reliability and validity. Internal consist-
ency ranged between 0.67 and 0.88 (Cronbach’s a). Intra-
class coefficient among appraisers ranged between 0.56 and
0.88. The quality of this guideline is low. Both domains ‘Scope
and Purpose’ and ‘Clarity of Presentation’ had the highest
quality scores (66.7% and 61.5%, respectively), whereas the
scores for ‘Applicability’, ‘Stakeholder Involvement’, ‘Rigour
of Development’ and ‘Editorial Independence’ were the
lowest (27%, 35%, 36.5%, and 40%, respectively).
Conclusions: The findings suggest that the quality of this
Clinical Practice Guideline is disappointingly low. To
improve the quality of current and future guidelines, the
AGREE II instrument is extremely recommended to be
incorporated as a gold standard for developing, evaluating
or updating the Palestinian Clinical Practice Guidelines.
Future guidelines can be improved by setting specific stra-
tegies to overcome implementation barriers with respect
to economic considerations, engaging of all relevant end-
users and patients, ensuring a rigorous methodology for
searching, selecting and synthesising the evidences and rec-
ommendations, and addressing potential conflict of inter-
ests within the development group.
Keywords
AGREE II, Clinical Practice Guideline, diabetes mellitus,
psychometric properties, methodological quality
Introduction
Diabetes mellitus (DM) is a rapidly growing public
health problem. It is a metabolic disease characterised
byhyperglycaemia resulting fromdefects in insulin secre-
tion, insulin action or both. ‘Long-term complications of
diabetes include retinopathywith potential loss of vision;
nephropathy leading to renal failure; peripheral neur-
opathy with risk of foot ulcers, amputations and high
incidence of cerebrovascular disease and hypertension’.1
The World Health Organization estimates that about
347 million people globally have diabetes and projects
that diabetes will be the seventh leading cause of death in
2030.2 Most diabetes deaths (more than 80%) occur in
low- and middle-income countries.2 In Palestine, the
prevalence rate was 10.5% in the West Bank and
11.8% in the Gaza Strip among the registered
Palestinian refugees aged 40 years and older.3 Abu-
Rmeileh et al.4 estimated the prevalence of DM in
Palestine at 20.8% and 23.4% in 2020 and 2030, respect-
ively.4 The PalestinianClinical PracticeGuideline (CPG)
forDMwas developed to promote evidence-basedmedi-
cine in screening, diagnosis, and treatment and to stand-
ardise the care provided for diabetic patients type 1 and
2. The Palestinian CPG was adapted from international
guidelines with extensive participation of local experts to
ensure the acceptance in, applicability to and consistency
with the Palestinian local context.5
CPGs are deﬁned as ‘systematically developed
statements to assist practitioners and patient deci-
sions about appropriate healthcare for speciﬁc cir-
cumstances’.6 It has been shown that CPGs are
eﬀective in promoting the quality of healthcare ser-
vices and improving patients’ outcomes.7 The large
numbers of the published CPGs have raised many
inquiries about their quality,8 and the method of
developing CPGs has been exposed to extensive
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criticism since high-quality CPGs should be evidence-
based, valid and generalisable to the target popula-
tion. In order to ensure standardised CPGs with
high quality, the recommendations should be valid,
transparent and applicable.9 Developing CPGs based
on the best available evidence is a determinant
for their trustworthiness.9 It is recognised that rando-
mised clinical trials are the basic blocks for guide-
line development. Many guidelines developers,
however, more likely developed the CPGs depending
on expert opinion or based on lower levels of evi-
dences.10 Such cases can result in biased
recommendations.10
Previous studies showed that the quality of CPGs
in diﬀerent clinical areas was suboptimal.11 Recent
studies evaluating the trustworthiness of CPGs have
found that guidelines contain incompatible recom-
mendations, show an inconsistency in selecting the
evidences, exhibit a lack of reliable and transparent
methodology in their development processes and
rarely have the declaration of any potential conﬂicts
of interest among members of the guideline devel-
opers.12 Such ﬁndings create CPGs with poor validity
and restrict their utilisation as evidence-based
resources for clinicians.12
The Appraisal of Guidelines for Research and
Evaluation (AGREE II) assessment tool is a vali-
dated questionnaire used to assess the methodo-
logical quality of CPGs.13 It has been adopted by
the World Health Organization for the assessment
of CPGs and is recognised now as the new inter-
national tool for the assessment of CPGs.13 To the
best of our knowledge, no study has investigated the
quality of the Palestinian CPG for DM based on the
AGREE II instrument. Therefore, and with the over-
all goal of improving the quality of the local and
national future CPGs, this study aims to assess the
methodological quality of the Palestinian CPG for
DM using the AGREE II instrument.
Methods
Structure of AGREE II instrument
The AGREE II is a 23-item tool comprising six qual-
ity domains followed by two overall assessment
items: Domain 1 ‘Scope and Purpose’ is concerned
with the overall aim of the guideline, the speciﬁc
health questions and the target population (three
items); Domain 2 ‘Stakeholder Involvement’ focuses
on the extent to which the guideline was developed by
the appropriate stakeholders and represents the views
of its intended users (three items); Domain 3 ‘Rigour
of Development’ relates to the process used to gather
and synthesise the evidence, the methods to formulate
the recommendations and to update them (eight
items); Domain 4 ‘Clarity and Presentation’ deals
with the language, structure and format of the guide-
line (three items); Domain 5 ‘Applicability’ pertains
to the likely barriers and facilitators to implementa-
tion, strategies to improve uptake and resource impli-
cations of applying the guideline (four items); and
Domain 6 ‘Editorial Independence’ is concerned
with the formulation of recommendations not being
unduly biased with competing interests (two items). A
seven-point Likert scale (ranged between score 7 for
strongly agree to score 1 for strongly disagree) is used
to score each domain item. The overall assessment
includes two items: the rating of the overall quality
of the guideline (with a scale ranging from 7 for
higher possible quality to 1 for lower possible quality)
and whether the guideline would be recommended for
use in practice, with a three-point scale (3 for not
recommended; 2 for recommended with modiﬁca-
tions; and 1 for recommended). In line with similar
studies, scores of 50% or less were deﬁned as poor
quality.14
Translation process
The AGREE II instrument has been formally trans-
lated into several languages (available at: http://www.
agreetrust.org). The Arabic translation process has
been led by the ﬁrst author (MR) and successfully
published at the AGREE Enterprise website in 2015
(available at: http://www.agreetrust.org/resource-
centre/agree-ii-translations/). The process of
AGREE II translation from English to Arabic was
mainly performed using the cross-cultural adaptation
standardised guideline,15 which comprises the follow-
ing steps: forward translation, back translation,
review by a committee of experts and pre-testing
(pilot study). Initially, the forward translation from
English into Arabic language was independently
done by two professional translators with Arabic
mother tongue (one of them was familiar with study
objectives as well guidelines development and evalu-
ation). A consensual ﬁrst draft translation was devel-
oped after examining by group of health experts.
Back translation for the ﬁrst draft was translated to
English by two translators with English mother
tongue (they did not participate in the ﬁrst phase of
translation and were neither familiar with AGREE II
nor study objectives). Discrepancies between the ori-
ginal English and all translated versions of AGREE
II were examined by a reviewing committee including
the ﬁrst author (MR), forward translators, one health
expert, one researcher and one linguist professional
to arrive at a consensual pre-ﬁnal draft Arabic
translation.
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In order to verify the applicability of the pre-ﬁnal
Arabic translated AGREE II instrument and test the
clarity and understandability of its items, pilot testing
took place, with a sample of four health professionals
(family physicians and staﬀ nurses) being selected to
use the pre-ﬁnal instrument in evaluating the CPG for
DM. Then they were asked to rate each item on a
Likert-type scale ranging from 1 (not clear or under-
stood) to 10 (completely clear and easily under-
stood).16 Results showed a mean clarity index of 8.5
(scale 1–10), indicating that the questionnaire was
easily understood by the target population.
Appraisal process
Sixteen appraisers were purposively selected (two
endocrinologists, eight family physicians, four aca-
demic professors (‘health experts’) and two experi-
enced nurses who work with chronic diseases) in
order to assess the methodological quality of the exist-
ing CPG for DM. Members of the guideline develop-
ment group were excluded to reduce any potential
bias. All appraisers were familiar with at minimum
the principles of guidelines development and research
methodology. Sixteen copies of Translated Arabic
Version of the AGREE II instrument accompanied
with 16 copies of the CPG for DM were provided to
the appraisers to independently assess its quality.
Based on the manual guide of the Translated Arabic
Version of the AGREE II (available at http://www.
agreetrust.org/resource-centre/agree-ii-translations/),
detailed descriptions and explanations on the meaning
of the whole AGREE II items were attached with each
copy (as advised by AGREE II enterprise) to ensure
appraisers’ understanding of the items and reduce the
inter-rater disagreement.
Data analysis
Parameters of construct and criterion validity were
used to assess the validity of the Translated Arabic
Version of the AGREE II instrument, whereas the
internal consistency and inter-rater agreement param-
eters were used to assess its reliability. The SPSS pro-
gram was used for all statistical analyses; p values of
0.05 or less were considered signiﬁcant. Descriptive
analysis values were mean, standard deviation and
minimum and maximum with 95% conﬁdence inter-
vals (CIs). Correlations analysis was performed using
Spearman’s rho and Kendall’s Tau B coeﬃcients.
Domain scores were calculated as recommended by
the AGREE Collaboration. Domain scores were cal-
culated by summing up all the scores of the individual
items in a domain and by scaling the total as a per-
centage of the maximum possible score for that
domain. The standardising was performed using the
following formula recommended by AGREE II enter-
prise: (obtained score–minimum possible score)/(max-
imum possible score–minimum possible score).
Validity analyses
Face validity. The Translated Arabic Version of the
AGREE II instrument with its translated user guide
was sent to 16 experts (academics and researchers) to
share their comments and feedback about clarity, sim-
plicity and easiness to understand of AGREE II items
and phrases of the user guide. The reviewers were
asked to rephrase any ambiguous item or item which
could not be understood.
Construct validity. Construct validity was assessed by
evaluating two assumptions. The ﬁrst one proposed
that presenting the key recommendations in sum-
marised tables, ﬂow charts and algorithms might
favourably aﬀect the appraisers’ perspective towards
the quality of this guideline. The second assumption
suggested that the explicit description of the guideline
external reviewers (e.g. number, qualiﬁcations, experi-
ences, aﬃliations) might aﬀect the appraisers’ perspec-
tive towards recommending the use of this guideline.
Criterion validity. Criterion validity was assessed in the
same manner as reported by the AGREE
Collaboration in their validation study.17
Assessment of criterion validity was assessed by cal-
culating the Kendall’s Tau B rank correlation coefE-
cients between the appraisers’ domains scores and the
overall assessment scores.
Reliability analyses
Two measures of reliability were conducted: (1) Using
mean item scores, the Cronbach  coefEcient was cal-
culated to measure internal consistency of each
domain of the Enal instrument where scores over
0.70 were considered acceptable, reﬂecting the internal
correlation between items of the same area. (2) ICC
with a 95% CI was calculated to assess the reliability
within each domain and to measure the inter-rater
reliability for each domain. ICC values above 0.75
were considered to represent good, 0.40–0.75 moderate
and <0.40 poor reliability.18
Results
Validity and reliability
Face validity. Items of the Translated Arabic Version
of the AGREE II instrument with its Arabic
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translated user guide were evaluated as clear and easy
to understand by all health experts. Only very minor
changes in the wording of a few items were
performed.
Construct validity. We observed a signiﬁcant association
between the overall quality assessment scores and
presenting the key recommendations in summarised
tables, ﬂow charts and algorithms (Spearman’s
rho¼ 0.51, p< 0.05). The association between recom-
mending the use of this guideline in practice and the
clear description of the guideline external reviewers
was signiﬁcant (Spearman’s rho¼ 0.73, p< 0.01).
Criterion validity. The correlation between domain
scores and overall quality assessment ranged between
low (0.18) to moderate (0.62). The highest correl-
ation being observed was for the Rigour of
Development which was the only domain whose cor-
relation reached the signiﬁcant level (Kendall’s Tau B
Coeﬃcient¼ 0.62, p¼ 0.003; Table 1).
Reliability. The overall internal consistency for domain
items was high (Cronbach’s a¼ 0.87) and for domains
scales ranged between 0.67 and 0.88 (Table 2). The
highest consistency was shown for the Rigour of
Development (Cronbach’s a¼ 0.88). The overall
agreement among reviewers was good (ICC¼ 0.82;
95% CI 0.67–0.92). The ICCs for domain scores
ranged between moderate and good (0.56–0.88;
Table 3). ICCs showed that appraisers reached
higher agreement when assessing the Rigour of
Development domain (r¼ 0.88).
Quality assessment
Table 4 shows the AGREE II domain scores of the
CPG for DM as evaluated by the 16 appraisers. In
general, it seems that the quality of the CPG for DM
was questionable when using the AGREE II instru-
ment. The overall average score was 45% and
Table 1. Correlation of domain scores with overall
assessment of AGREE II.
Domain
Kendall’s
Tau-B
coefficient Sig (p)
Domain 1 Scope and Purpose 0.21 0.32
Domain 2 Stakeholder Involvement 0.18 0.38
Domain 3 Rigour of Development 0.62 0.003
Domain 4 Clarity of Presentation 0.31 0.13
Domain 5 Applicability 0.24 0.23
Domain 6 Editorial Independence 0.26 0.22
Kendall’s Tau B correlations were conducted between the mean rating
of the overall assessment of the CPG across all appraisers as compared
to the mean of each domain score.
Table 2. Internal consistency of AGREE II instrument domain
scales.
Domain
Number
of items
Cronbach’s
alpha
Domain 1 Scope and Purpose 3 0.74
Domain 2 Stakeholder
Involvement
3 0.72
Domain 3 Rigour of
Development
8 0.88
Domain 4 Clarity of
Presentation
3 0.67
Domain 5 Applicability 4 0.83
Domain 6 Editorial
Independence
2 0.70
Cronbach’s alpha was calculated for if item deleted.
Table 3. Inter-rater reliability of AGREE II instrument
domain scores.
Domain
Number
of items
ICC
coefficient
95%
Confidence
interval
Domain 1 Scope
and Purpose
3 0.75 0.42–0.90
Domain 2
Stakeholder
Involvement
3 0.56 0.05–0.83
Domain 3 Rigour of
Development
8 0.88 0.87–0.95
Domain 4 Clarity of
Presentation
3 0.65 0.24–0.86
Domain 5
Applicability
4 0.83 0.59–0.92
Domain 6 Editorial
Independence
2 0.63 0.09–0.87
Intra-class correlation (ICC) coefficient calculated using absolute
agreement.
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domain standardised scores ranged between 27% and
66.7%. The highest domain scores were the Scope
and Purpose (66.7%) and clarity of presentation
(61.5%), whereas the other four domains
(Applicability, Stakeholder Involvement, Rigour of
Development and Editorial Independence) were less
than 50%. This implies that less than 50% of rigor-
ous criteria were met for developing this guideline.
The overall mean score of guideline quality is 4.19.
The use of this guideline in practice was recom-
mended with modiﬁcations by 12 appraisers and
not recommended by 4 appraisers.
Discussion
To the best of our knowledge, this is the ﬁrst study
critically evaluating the methodological quality of the
current CPG for DM using the AGREE II instru-
ment. An Arabic version of the AGREE II instru-
ment was developed and tested in a standardised
manner. The study ﬁndings suggest that the
Translated Arabic Version of the AGREE II instru-
ment was reliable and valid when used in assessing
the CPG for DM. Obviously, it sounds that the reli-
ability scores of the Translated Arabic Version of the
AGREE II have been favourably inﬂuenced due to
the Arabic translated user guide attached to each item
of the instrument. A study aiming to assess the eﬀects
of Korean AGREE II score guide, which provides
detailed evaluation criteria for each item, showed
higher reliability at all guidelines.19 In this guideline,
the internal consistency of each domain was accept-
able and similar to ﬁndings of AGREE
Collaboration.17 The inter-rater reliability was good
with the domains of Rigour of Development (¼0.88),
Applicability (r¼ 0.83) and Scope and Purpose
(r¼ 0.75), and moderate with the rest of domains.
Improvements in reliability of these domains might
be anticipated with further training to guidelines
appraisers as training can minimise the opportunities
of misinterpretation. The construct validity had two
assumptions: in the ﬁrst one, the ﬁndings showed a
signiﬁcant association between the overall quality
assessment scores and presenting the key recommen-
dations in summarised tables, ﬂow charts and algo-
rithms. Cautiously, it seems that the presence of
summarised tables, ﬂow charts or algorithms was
more likely to favourably aﬀect the appraisers’ per-
spective towards the quality of this guideline. In the
second assumption, we also observed that the associ-
ation between recommending the use of this guideline
in practice after modiﬁcation and the clear descrip-
tion of the guideline external reviewers was signiﬁ-
cant. It can be said that the clear description of the
guideline external reviewers (e.g. numbers, qualiﬁca-
tions, experiences, aﬃliations) played a notable role
in recommending the use of this guideline. For criter-
ion validity, the correlation between the domain
scores and the overall quality assessment was only
signiﬁcant for Rigour of Development (Kendal Tau
B¼ 0.62, p¼ 0.003). Interpreting the variation in the
results of validity measures appears to be diﬃcult.
Even the AGREE Collaboration’s studies were not
able to demonstrate conclusively the validity of the
AGREE instrument since they admitted that valid-
ation is a challenging task.17
This study shows that the methodological quality
of the current CPG for DM was disappointingly low
when using the AGREE II instrument. The low qual-
ity of this guideline could be explained by the fact
that the AGREE II instrument was not used in
developing or updating the current guideline. The
use of the AGREE II instrument already showed evi-
dence of improving the quality of other guidelines,
Table 4. AGREE II domain scores of the CPG for DM.
Domain
Standardised
scores (%)
Overall average
AGREE II
score (%)
Overall quality
score (range 1–7)
M SD
Overall assessment
‘Recommendation
of Use’ (n¼ 16)
Domain 1 Scope and Purpose 66.7%
45% 4.19 0.83
Recommended with
modifications (n¼ 12)
Not recommended (n¼ 4)
Domain 2 Stakeholder Involvement 35%
Domain 3 Rigour of Development 36.5%
Domain 4 Clarity of Presentation 61.5%
Domain 5 Applicability 27%
Domain 6 Editorial Independence 40%
A standardised formula was used as recommended by AGREE Enterprise to assess the quality of guidelines.
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such as guidelines on the management of low back
pain.14 Another possible explanation is poor report-
ing even if there were reasonable endeavours to
develop it. Assessing the methodological quality of
a guideline relies heavily on how well documented
the guideline development process is.20
The present study results are widely consistent
with previous appraisals evaluating various topics
of CPGs.21 In previous appraisals, both domains,
the ‘Scope and purpose’ and ‘Clarity of presentation’
had the highest scores, whereas the scores for
‘Applicability’, ‘Stakeholder Involvement’, ‘Rigour
of Development’, and ‘Editorial Independence’ were
the lowest. Although both domains ‘Scope and
Purpose’ and ‘Clarity of Presentation’ had acceptable
scores, this guideline inadequately reported on the
domains ‘Stakeholder Involvement,’ ‘Rigour of
Development,’ ‘Applicability’ and ‘Editorial
Independence’. In particular, the low score on the
largest domain Rigour of Development (36.5%) is
causing a remarkable concern because explicit
descriptions of how the available evidence was iden-
tiﬁed, selected and synthesised are important for the
development of valid and reliable evidence-based rec-
ommendations. Systematic reviews should form the
basis for all high-quality CPGs.22 Apparently, this
was not the case with this guideline where searching
and selecting the evidence as well as formulating
transparent recommendations did not pass through
a rigorous path. A more logical explanation for the
low score of this crucial domain is the limited experi-
ence in synthesising the evidence of randomised clin-
ical trials and systematic reviews. Poor guidelines
might be a result of the lack of methodological
expertise among guideline developers. The quality
may be improved by involving search experts and
methodologists in the guideline development process,
as well as clarifying the methods of guideline devel-
opment.23 It is expected that the current guideline
was largely based on experts’ opinion rather than
rigorous criteria for evidence synthesis. Guidelines
developed by expert consensus or using nonsyste-
matic methodology may create biased recommenda-
tions and malpractice.24
Another extremely worrisome result is the lowest
domain score of the Applicability (27%) since con-
sidering the tools and the potential resources for
applying the recommendations as well as providing
criteria for monitoring the performance can facilitate
the implementation of the recommendations. In low-
income countries, developing CPGs with high quality
is more challenging because of the limited resources
and capacity.25 Inclusion of cost and resource infor-
mation within CPGs can encourage the professionals
to transparently select among treatment alternatives
and it is quite important in the light of progress in
medical technology and increasing healthcare costs.26
A meta-review of 42 studies in which 626 guidelines
on diﬀerent topics published in various countries
from 1980 to 2007 were assessed with the AGREE
instrument found that most guidelines achieved
low scores for applicability (mean 22%, 95% CI
20.4%–23.9%) compared to all other domains.21
Poor applicability is not due to an inherent ﬂaw of
the well-validated AGREE II. This is most likely due
to the poor deﬁning of implementation strategies for
addressing the organisational barriers and cost impli-
cations during the guidelines development process.27
The lowest score of ‘Applicability’ in this appraisal
suggests that the guideline developers did not pay
suﬃcient attention to the possible factors aﬀecting
the practical implementation of guideline recommen-
dations. Guidelines that fail to address these areas
may lead to poor uptake by healthcare professionals
and therefore have a limited contribution to improving
healthcare quality.28 Another possible explanation is
the inadequate pilot testing of this guideline, and if it
was piloted at a small scale, it seems that gathering and
analysing the feedback from users was at the lowest
levels. Feedback of pilot studies can help in formulat-
ing intervention strategies to support clinical
guidelines.29
A much more expected ﬁnding is the low score of
Stakeholder Involvement (35%) which could reﬂect
the inadequate consideration of patients’ views and
preferences during guideline development as well as
the unclear description of the target users (e.g. doc-
tors, nurses, pharmacists, etc.). It has been shown
that inclusion of patients’ views in a guideline devel-
opment has crucial implications for the success of
guidelines implementation.30 It seems that in the
Palestinian organisational culture, engagement of
patients in the guidelines development process,
healthcare planning or the process of strategic plan-
ning and considering their views or expectations all
remain a challenge. Similarly, in other low- and
middle-income countries, engagement of patients or
end-users may not be considered in guidelines devel-
opment that targets diﬀerent places.31 Poor engage-
ment of patient representatives during guideline
development could make the patients uncommitted
to guideline recommendations. In a disease such as
DM, non-adherence to treatments can have signiﬁcant
impact on morbidity and mortality. Considering
patient preferences on treatment decisions is associated
with better clinical outcomes.32
One last low score is the Editorial Independence
(40%) which focuses on how far the views of a fund-
ing body aﬀected the ﬁnal recommendations and how
guideline developers declared the conﬂict of interest.
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Conﬂicts of interest are the most common source of
bias in guideline development, which may result in
biased recommendations.33 The suboptimal score of
this domain could be explained in two possible ways:
either the guideline development group members
were not aware of conﬂict of interest disclosures, or
they preferred not to follow the explicit manner of
declaration. It could be that guideline developers
did not follow the systematic path of reporting the
conﬂict of interest.34 However, a previous study
found that conﬂicts of interest are widely common
among CPGs in a variety of clinical areas.35
Although this guideline was funded by the World
Bank, it is still unclear to what extent it has been
inﬂuenced by the donor’s agenda or what measures
were taken to minimise the inﬂuence of competing
interests on guideline development or formulation
of the recommendations.
A limitation of the present study is that the apprai-
sers did not receive a speciﬁc training course about
the AGREE II instrument. However, the user guide
was used to overcome such shortcoming. Another
limitation was that the AGREE II instrument
lacked any criteria necessary to assign a score for
the last two overall quality assessments.
Conclusion
The Translated Arabic Version of the AGREE II
instrument is a satisfactory, valid and reliable tool to
assess the methodological quality of Palestinian CPG
for DM. By using the Translated Arabic Version of
the AGREE II instrument, this study shows that the
quality of this guideline is disappointingly low. To
improve the quality of our current and future guide-
lines, a more systematic and rigorous approach in syn-
thesis and reporting of evidence and recommendations
is extremely advised. The AGREE II instrument
should be incorporated as a gold standard for develop-
ing, evaluating or updating the Palestinian CPGs.
Instruments such as AGREE II, GRADE and
PRISMA could be quite useful tools and contribute
positively in the improvement of guidelines’ quality
and transparency. Considering the potential resources
and designing monitoring measures can strengthen its
implementation. A systematic involvement of diﬀerent
healthcare professionals and patients in the develop-
ment and evaluation of guidelines is necessary to
explore their experiences and expectations. Extra
attention for updating procedures and managing con-
ﬂict of interest are exceedingly recommended.
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